Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS)
India · Delayed Price · Currency is INR 101.00
-1.63 (-1.59%)
Sep 24, 2026, 3:29 PM IST
NSE:AAREYDRUGS Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 2,903 | 1,448 | 942 | 1,253 | 601 | 1,051 | |
Market Cap Growth | 29.14% | 53.63% | -24.82% | 108.61% | -42.83% | 93.71% |
Enterprise Value | 3,476 | 1,935 | 1,314 | 1,553 | 842 | 1,276 |
Last Close Price | 102.63 | 50.75 | 33.51 | 43.65 | 24.00 | 41.45 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 80.19 | 36.49 | 23.42 | 26.76 | 15.93 | 16.03 |
PS Ratio | 0.70 | 0.31 | 0.20 | 0.31 | 0.14 | 0.21 |
PB Ratio | 1.93 | 0.96 | 0.68 | 0.94 | 0.51 | 0.93 |
P/TBV Ratio | 1.93 | 0.96 | 0.68 | 0.94 | 0.51 | 0.93 |
P/FCF Ratio | - | - | 18.49 | - | - | - |
P/OCF Ratio | 28.63 | 14.28 | 9.15 | - | - | 210.69 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 0.84 | 0.41 | 0.28 | 0.39 | 0.20 | 0.26 |
EV/EBITDA Ratio | 52.20 | 22.42 | 18.61 | 13.54 | 10.18 | 10.62 |
EV/EBIT Ratio | 97.11 | 33.48 | 25.68 | 15.89 | 12.58 | 12.73 |
EV/FCF Ratio | - | - | 25.78 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.40 | 0.39 | 0.31 | 0.24 | 0.32 | 0.13 |
Debt / EBITDA Ratio | 9.12 | 6.75 | 6.17 | 2.73 | 4.56 | 1.18 |
Debt / FCF Ratio | - | - | 8.55 | - | - | - |
Net Debt / Equity Ratio | 0.38 | 0.37 | 0.29 | 0.21 | 0.31 | 0.12 |
Net Debt / EBITDA Ratio | 8.61 | 6.36 | 5.71 | 2.48 | 4.43 | 1.16 |
Net Debt / FCF Ratio | - | -24.17 | 7.91 | -7.66 | -15.74 | -8.21 |
Asset Turnover | - | 1.61 | 1.60 | 1.35 | 1.56 | 2.06 |
Inventory Turnover | - | 5.56 | 6.43 | 5.57 | 6.66 | 9.16 |
Quick Ratio | - | 0.92 | 0.92 | 1.13 | 1.14 | 1.08 |
Current Ratio | - | 1.81 | 1.78 | 1.70 | 1.61 | 1.73 |
Return on Equity (ROE) | - | 2.75% | 2.97% | 3.74% | 3.26% | 6.17% |
Return on Assets (ROA) | - | 1.23% | 1.08% | 2.05% | 1.56% | 2.62% |
Return on Invested Capital (ROIC) | 1.49% | 2.21% | 1.98% | 5.43% | 2.98% | 5.37% |
Return on Capital Employed (ROCE) | - | 3.80% | 3.60% | 7.10% | 5.40% | 8.50% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 1.25% | 2.74% | 4.27% | 3.74% | 6.28% | 6.24% |
FCF Yield | -0.78% | -1.57% | 5.41% | -2.96% | -3.87% | -1.62% |
Buyback Yield / Dilution | -1.07% | - | -11.96% | 0.26% | -5.84% | -2.95% |
Total Shareholder Return | -1.07% | - | -11.96% | 0.26% | -5.84% | -2.95% |